IP Library › Granted Patent US 11,007,228
Granted Patent B2
US 11,007,228 · App. 16/075,517 · Granted May 18, 2021

Pharmaceutical composition containing stem cell in which vascular endothelial growth factor is overexpressed as effective ingredient for preventing or treating neurodegenerative disease

Inventors: Jae Sung Bae (Daegu, KR); Hee Kyung Jin (Daegu, KR); Min Hee Park (Gyeongsangbuk-do, KR)
Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
A61K35/30A61K9/00A61K9/0085A61K35/12A61K35/28A61K35/545A61P25/28C07K14/49
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,007,228
App. No.
16/075,517
Granted
May 18, 2021
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition containing stem cells in which vascular endothelial growth factor (VEGF) is overexpressed as an effective ingredient for preventing or treating neurodegenerative diseases. The stem cells in which VEGF is overexpressed according to the present invention effectively act against the neurodegenerative disease-induced VEGF reduction of neural stem cells in the SVC to inhibit the abnormal migration of neural stem cells, suppress inflammatory responses, and restrain the accumulation of cholesterol and spingolipids in the cerebral cortex, thus restoring the behavior exercise capacity of animal models, whereby the pharmaceutical composition can be used as an effective therapeutic agent for neurodegenerative diseases.

Claims (5)

1. A method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering an effective amount of a composition comprising stem cells overexpressing vascular endothelial growth factor (VEGF) as an active ingredient to a subventricular zone (SVZ) of the subject, wherein the neurodegenerative disease is selected from the group consisting of Niemann-Pick disease, Gaucher disease, Fabry disease, Tay-Sachs disease, and Sandhoff disease.

2. The method of claim 1 , wherein the stem cells are at least any one selected from the group consisting of adult stem cells, embryonic stem cells, mesenchymal stem cells, tumor stem cells, and induced pluripotent stem cells.

3. The method of claim 2 , wherein the adult stem cells are neural stem cells or neural progenitor cells.

4. The method of claim 1 , wherein the stem cells overexpressing the vascular endothelial growth factor (VEGF) reduce a cerebral inflammation and inhibit cholesterol or sphingolipid accumulation.

5. The method of claim 1 , wherein the composition is a pharmaceutical composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: BAE, JAE SUNG; JIN, HEE KYUNG; PARK, MIN HEE
To: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Reel/Frame 047078/0980 →
Priority Claims (1)
KR 10-2016-0015093 · Feb 5, 2016 · national
Continuity (1)
Related Publication 20190030082A1 · Jan 31, 2019